As an investor in ChromaDex (CDXC), and a user of their lead product Tru Niagen, I'm a firm believer in the health benefits of Nicotinamide Riboside (NR). NR in its consumer form is more commonly known as Niagen, which is...
ChromaDex (CDXC) reported earnings yesterday. As expected, they lost money during this period where they are investing in the development of Tru Niagen as a potential blockbuster supplement. Looking beyond the bottom line, which is basically irrelevant at this...
IRVINE, Calif., June 12, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today that it has signed...
Tailwinds' Take: CDXC stock has been weak with a combination of lack of news and forecasted sales not picking up until Q3 weighing on the stock. Summer doldrums will likely be your buying opportunity here. IRVINE, Calif., May 29, 2018 (GLOBE NEWSWIRE)...
I'm just going to lay it out there with the risk of being viewed as overly promotional: Nicotinamide Ribosome (otherwise known as Niagen) has produced some very positive, albeit early-stage, results as a potential cure for Alzheimer's. This is potentially...
This morning we have added Chromadex to the Tailwinds Select Portfolio at a price of $3.91. Chromadex holds the worldwide rights to Niagen, a member of the vitamin B-3 family that helps promote healthier living and longer lives. CDXC...
Many companies in the Tailwinds (TW) coverage universe reported earnings this last week. Here we discuss each of their results (alphabetically), along with a preview of what we expect going forward. AQMS: from TW's perspective, this quarter is yet one...
Yesterday Chromadex announced the pricing of a private placement for $23M dollars. This deal was significant to the Company in that they have padded their purse at a time when they are rolling out Tru Niagen on a global...
Tailwinds' Take: the implications of this study are potentially massive. It truly appears that NR has many positive effects and is well on its way to becoming a blockbuster supplement. No side effects, many benefits. There appears to be...
Tailwinds' Take: this is not a shocking number, but would have liked them to guide to growth resuming sooner. We had trimmed after the Colorado study and will likely buy it back on weakness. IRVINE, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- ChromaDex...